2nd Quarter - Report
REGENERON PHARMACEUTICALS, INC for REGENERON PHARMACEUTICALS, INC
Income
—
Expenses
$340,000
Expense method
A: Lobbying Disclosure Act definitions
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Biodefense issues relating to biopharmaceutical manufacturers; tax and incentives; issues related to drug manufacturing, access, and pricing; pandemic response measures, including manufacturing and budget appropriation issues
| Lobbyist | Covered position, as disclosed |
|---|---|
| MAYA BERMINGHAM | — |
| KATHERINE HADDAD | — |
| VALERIE VOLPE | — |
Medicare/Medicaid MMM
Medicare and Medicaid issues relating to biopharmaceutical manufacturers, including ancillary care
| Lobbyist | Covered position, as disclosed |
|---|---|
| KATHERINE HADDAD | — |
| VALERIE VOLPE | — |
Copyright/Patent/Trademark CPT
Patent issues relating to biopharmaceutical manufacturers; intellectual property rights
| Lobbyist | Covered position, as disclosed |
|---|---|
| MAYA BERMINGHAM | — |
| VALERIE VOLPE | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.